The role of cellular senescence in neurodegenerative diseases

Wu, Qinghua,Jomova, Klaudia

DOI: https://doi.org/10.1007/s00204-024-03768-5

2024-05-16

Archives of Toxicology

Abstract:Increasing evidence has revealed that cellular senescence drives NDs, including Alzheimer's disease (AD) and Parkinson's disease. Different senescent cell populations secrete senescence-associated secretory phenotypes (SASP), including matrix metalloproteinase-3, interleukin (IL)-1α, IL-6, and IL-8, which can harm adjacent microglia. Moreover, these cells possess high expression levels of senescence hallmarks (p16 and p21) and elevated senescence-associated β-galactosidase activity in in vitro and in vivo ND models. These senescence phenotypes contribute to the deposition of β-amyloid and tau-protein tangles. Selective clearance of senescent cells and SASP regulation by inhibiting p38/mitogen-activated protein kinase and nuclear factor kappa B signaling attenuate β-amyloid load and prevent tau-protein tangle deposition, thereby improving cognitive performance in AD mouse models. In addition, telomere shortening, a cellular senescence biomarker, is associated with increased ND risks. Telomere dysfunction causes cellular senescence, stimulating IL-6, tumor necrosis factor-α, and IL-1β secretions. The forced expression of telomerase activators prevents cellular senescence, yielding considerable neuroprotective effects. This review elucidates the mechanism of cellular senescence in ND pathogenesis, suggesting strategies to eliminate or restore senescent cells to a normal phenotype for treating such diseases.

toxicology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the mechanism of action of cellular senescence in neurodegenerative diseases (NDs) and to propose the possibility of treating these diseases by eliminating or restoring senescent cells.

Specifically, the paper mainly focuses on the following aspects:

1. **The association between cellular senescence and neurodegenerative diseases**:
- The paper points out that there is increasing evidence that cellular senescence drives neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
- Different types of senescent cells secrete the senescence - associated secretory phenotype (SASP), such as matrix metalloproteinase - 3 (MMP - 3), interleukin (IL) - 1α, IL - 6 and IL - 8, which can damage neighboring microglia.
- These senescent phenotypes promote the formation of β - amyloid deposition and tau protein tangles.

2. **The molecular mechanism of cellular senescence**:
- The paper discusses in detail the molecular mechanism of cellular senescence in neurodegenerative diseases, especially its role in Aβ accumulation, tau - mediated diseases and telomere damage.
- For example, selective elimination of senescent cells and regulation of SASP by inhibiting the p38/mitogen - activated protein kinase (MAPK) and nuclear factor kappa B (NF - κB) signaling pathways can reduce the β - amyloid load and prevent tau protein tangle deposition, thereby improving the cognitive function of AD mouse models.

3. **Diagnosis and treatment strategies**:
- The paper proposes diagnosis and treatment strategies for cellular senescence, including the use of senotherapeutics (such as senolytics and senomorphics) to regulate the cellular senescence process.
- Specific drugs such as dasatinib plus quercetin (D + Q) have been proven to be effective in animal models and are undergoing clinical trials to evaluate their safety and efficacy.

4. **Future research challenges**:
- Finally, the paper outlines the main challenges for future experiments, emphasizing that eliminating senescent cells may be an important goal for treating neurodegenerative diseases.

In summary, this paper aims to comprehensively overview the latest research progress of cellular senescence in the pathogenesis of neurodegenerative diseases and explore potential treatment strategies for intervening in cellular senescence.